Characterization of Influenza Vaccine Immunogenicity Using Influenza Antigen Microarrays

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Price, Jordan V ^a,b   Jarrell, Justin A ^a,b   Furman, David ^a,b   Kattah, Nicole H ^a,b   Newell, Evan ^a,b   Dekker, Cornelia L ^a,b   Davis, Mark M ^a,b   Utz, Paul J ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ;

ACCURACY; AGE DISTRIBUTION; ANTIBODY TITER; ANTIGEN ANTIBODY REACTION; ARTICLE; CORRELATION ANALYSIS; FEMALE; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; IMMUNOREACTIVITY; INFLUENZA A (H1N1); INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; MICROARRAY ANALYSIS; NORMAL HUMAN; OUTCOME ASSESSMENT; PREDICTION; SINGLE DRUG DOSE; VALIDATION PROCESS; VIRUS NEUTRALIZATION; VIRUS STRAIN;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMINO ACID SEQUENCE; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; EPITOPES; FEMALE; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; LINEAR MODELS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; PEPTIDES; PROTEIN ARRAY ANALYSIS; PROTEOMICS; VACCINATION; YOUNG ADULT;

EID: 84878448792     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0064555     Document Type: Article

References (54)

1. Couch RB, (2008) Seasonal inactivated influenza virus vaccines. Vaccine 26: D5-D9.
2. Goodwin K, Viboud C, Simonsen L, (2006) Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine 24: 1159-1169.
3. He XS, Holmes TH, Sasaki S, Jaimes MC, Kemble GW, et al. (2008) Baseline Levels of Influenza-Specific CD4 Memory T-Cells Affect T-Cell Responses to Influenza Vaccines. Plos One 3.
4. Nabel GJ, Fauci AS, (2010) Induction of unnatural immunity: prospects for a broadly protective universal influenza vaccine. Nature medicine 16: 1389-1391.
5. Wrammert J, Koutsonanos D, Li GM, Edupuganti S, Sui J, et al. (2011) Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. The Journal of experimental medicine 208: 181-193.
6. Sasaki S, He XS, Holmes TH, Dekker CL, Kemble GW, et al. (2008) Influence of Prior Influenza Vaccination on Antibody and B-Cell Responses. Plos One 3.
7. Davis MM, (2008) A Prescription for Human Immunology. Immunity 29: 835-838.
8. Moxon ER, Siegrist CA, (2011) New Decade of Vaccines 1 The next decade of vaccines: societal and scientific challenges. Lancet 378: 348-359.
9. Salomon R, Webster RG, (2009) The influenza virus enigma. Cell 136: 402-410.
10. Webster R, Cox N, Stohr K (2002) WHO Manual on Animal Influenza Diagnosis and Surveillance.
11. Mace CR, Topham DJ, Mosmann TR, Quataert SA, Treanor JJ, et al. (2011) Label-free, arrayed sensing of immune response to influenza antigens. Talanta 83: 1000-1005.
12. Keynan Y, Bodnarchuk T, Wayne S, Li Y, Fowke KR, (2011) Evaluation of influenza-specific humoral response by microbead array analysis. The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale/AMMI Canada 22: 25-29.
13. Legutki JB, Magee DM, Stafford P, Johnston SA, (2010) A general method for characterization of humoral immunity induced by a vaccine or infection. Vaccine 28: 4529-4537.
14. Robinson WH, DiGennaro C, Hueber W, Haab BB, Kamachi M, et al. (2002) Autoantigen microarrays for multiplex characterization of autoantibody responses. Nat Med 8: 295-301.
15. Hueber W, Kidd BA, Tomooka BH, Lee BJ, Bruce B, et al. (2005) Antigen microarray profiling of autoantibodies in rheumatoid arthritis. Arthritis and rheumatism 52: 2645-2655.
16. Price JV, Tangsombatvisit S, Xu G, Yu J, Levy D, et al. (2012) On silico peptide microarrays for high-resolution mapping of antibody epitopes and diverse protein-protein interactions. Nature medicine.
17. Li L, Wadia P, Chen R, Kambham N, Naesens M, et al. (2009) Identifying compartment-specific non-HLA targets after renal transplantation by integrating transcriptome and "antibodyome" measures. Proceedings of the National Academy of Sciences of the United States of America 106: 4148-4153.
18. Butte AJ, Sigdel TK, Wadia PP, Miklos DB, Sarwal MM (2011) Protein microarrays discover angiotensinogen and PRKRIP1 as novel targets for autoantibodies in chronic renal disease. Molecular & cellular proteomics: MCP 10: M110 000497.
19. Neuman de Vegvar HE, Amara RR, Steinman L, Utz PJ, Robinson HL, et al. (2003) Microarray profiling of antibody responses against simian-human immunodeficiency virus: postchallenge convergence of reactivities independent of host histocompatibility type and vaccine regimen. Journal of virology 77: 11125-11138.
20. Bua DJ, Kuo AJ, Cheung P, Liu CL, Migliori V, et al. (2009) Epigenome microarray platform for proteome-wide dissection of chromatin-signaling networks. Plos One 4: e6789.
21. Levy D, Kuo AJ, Chang Y, Schaefer U, Kitson C, et al. (2011) Lysine methylation of the NF-kappaB subunit RelA by SETD6 couples activity of the histone methyltransferase GLP at chromatin to tonic repression of NF-kappaB signaling. Nature immunology 12: 29-36.
22. Thiele A, Zerweck J, Weiwad M, Fischer G, Schutkowski M, (2009) High-density peptide microarrays for reliable identification of phosphorylation sites and upstream kinases. Methods in molecular biology 570: 203-219.
23. Balboni I, Chan SM, Kattah M, Tenenbaum JD, Butte AJ, et al. (2006) Multiplexed protein array platforms for analysis of autoimmune diseases. Annu Rev Immunol 24: 391-418.
24. Govaert TM, Thijs CT, Masurel N, Sprenger MJ, Dinant GJ, et al. (1994) The efficacy of influenza vaccination in elderly individuals. A randomized double-blind placebo-controlled trial. JAMA: the journal of the American Medical Association 272: 1661-1665.
25. Beyer WEP, Palache AM, Luchters G, Nauta J, Osterhaus ADME, (2004) Seroprotection rate, mean fold increase, seroconversion rate: which parameter adequately expresses seroresponse to influenza vaccination? Virus Research 103: 125-132.
26. Friedman J, Hastie T, Tibshirani R, (2010) Regularization Paths for Generalized Linear Models via Coordinate Descent. Journal of statistical software 33: 1-22.
27. Skehel JJ, Wiley DC, (2000) Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annual review of biochemistry 69: 531-569.
28. Khurana S, Suguitan AL, Rivera Y, Simmons CP, Lanzavecchia A, et al. (2009) Antigenic Fingerprinting of H5N1 Avian Influenza Using Convalescent Sera and Monoclonal Antibodies Reveals Potential Vaccine and Diagnostic Targets. Plos Medicine 6.
29. Einhauer A, Jungbauer A, (2001) The FLAG (TM) peptide, a versatile fusion tag for the purification of recombinant proteins. Journal of Biochemical and Biophysical Methods 49: 455-465.
30. Field J, Nikawa J, Broek D, Macdonald B, Rodgers L, et al. (1988) Purification of a Ras-Responsive Adenylyl Cyclase Complex from Saccharomyces-Cerevisiae by Use of an Epitope Addition Method. Molecular and Cellular Biology 8: 2159-2165.
31. Sasaki S, Sullivan M, Narvaez CF, Holmes TH, Furman D, et al. (2011) Limited efficacy of inactivated influenza vaccine in elderly individuals is associated with decreased production of vaccine-specific antibodies. Journal of Clinical Investigation 121: 3109-3119.
32. de Bruijn IA, Remarque EJ, Jol-van der Zijde CM, van Tol MJ, Westendorp RG, et al. (1999) Quality and quantity of the humoral immune response in healthy elderly and young subjects after annually repeated influenza vaccination. The Journal of infectious diseases 179: 31-36.
33. McElhaney JE, Meneilly GS, Lechelt KE, Beattie BL, Bleackley RC, (1993) Antibody response to whole-virus and split-virus influenza vaccines in successful ageing. Vaccine 11: 1055-1060.
34. Chen WH, Cross AS, Edelman R, Sztein MB, Blackwelder WC, et al. (2011) Antibody and Th1-type cell-mediated immune responses in elderly and young adults immunized with the standard or a high dose influenza vaccine. Vaccine 29: 2865-2873.
35. Benjamini Y, Hochberg Y, (1995) Controlling the False Discovery Rate- a Practical and Powerful Approach to Multiple Testing. Journal of the Royal Statistical Society Series B-Methodological 57: 289-300.
36. Krause JC, Tsibane T, Tumpey TM, Huffman CJ, Basler CF, et al. (2011) A Broadly Neutralizing Human Monoclonal Antibody That Recognizes a Conserved, Novel Epitope on the Globular Head of the Influenza H1N1 Virus Hemagglutinin. Journal of virology 85: 10905-10908.
37. Xu R, Ekiert DC, Krause JC, Hai R, Crowe JE, et al. (2010) Structural Basis of Preexisting Immunity to the 2009 H1N1 Pandemic Influenza Virus. Science 328: 357-360.
38. Weis W, Brown JH, Cusack S, Paulson JC, Skehel JJ, et al. (1988) Structure of the influenza virus haemagglutinin complexed with its receptor, sialic acid. Nature 333: 426-431.
39. Stevens J, Blixt O, Tumpey TM, Taubenberger JK, Paulson JC, et al. (2006) Structure and receptor specificity of the hemagglutinin from an H5N1 influenza virus. Science 312: 404-410.
40. Ge X, Gebe JA, Bollyky PL, James EA, Yang J, et al. (2010) Peptide-MHC cellular microarray with innovative data analysis system for simultaneously detecting multiple CD4 T-cell responses. PloS one 5: e11355.
41. Zhao R, Cui S, Guo L, Wu C, Gonzalez R, et al. (2011) Identification of a highly conserved H1 subtype-specific epitope with diagnostic potential in the hemagglutinin protein of influenza A virus. PloS one 6: e23374.
42. Richards KA, Chaves FA, Sant AJ, (2011) The memory phase of the CD4 T-cell response to influenza virus infection maintains its diverse antigen specificity. Immunology 133: 246-256.
43. Tibshirani R, (1996) Regression shrinkage and selection via the Lasso. Journal of the Royal Statistical Society Series B-Methodological 58: 267-288.
44. Hoerl AE, Kennard RW (1970) Ridge Regression- Biased Estimation for Nonorthogonal Problems. Technometrics 12: 55-&.
45. McElhaney JE, (2011) Influenza vaccine responses in older adults. Ageing Research Reviews 10: 379-388.
46. Throsby M, van den Brink E, Jongeneelen M, Poon LLM, Alard P, et al. (2008) Heterosubtypic Neutralizing Monoclonal Antibodies Cross-Protective against H5N1 and H1N1 Recovered from Human IgM(+) Memory B Cells. Plos One 3.
47. Corti D, Voss J, Gamblin SJ, Codoni G, Macagno A, et al. (2011) A Neutralizing Antibody Selected from Plasma Cells That Binds to Group 1 and Group 2 Influenza A Hemagglutinins. Science 333: 850-856.
48. Liskamp RMJ, Rijkers DTS, Kruijtzer JAW, Kemmink J, (2011) Peptides and Proteins as a Continuing Exciting Source of Inspiration for Peptidomimetics. Chembiochem 12: 1626-1653.
49. Liotta LA, Espina V, Mehta AI, Calvert V, Rosenblatt K, et al. (2003) Protein microarrays: meeting analytical challenges for clinical applications. Cancer cell 3: 317-325.
50. Tabakman SM, Lau L, Robinson JT, Price J, Sherlock SP, et al. (2011) Plasmonic substrates for multiplexed protein microarrays with femtomolar sensitivity and broad dynamic range. Nature communications 2: 466.
51. Nakaya HI, Wrammert J, Lee EK, Racioppi L, Marie-Kunze S, et al. (2011) Systems biology of vaccination for seasonal influenza in humans. Nature immunology 12: 786-U149.
52. Querec TD, Akondy RS, Lee EK, Cao WP, Nakaya HI, et al. (2009) Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nature immunology 10: 116-125.
53. Gaucher D, Therrien R, Kettaf N, Angermann BR, Boucher G, et al. (2008) Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses. Journal of Experimental Medicine 205: 3119-3131.
54. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morbidity and mortality weekly report 60: 1128-1132.